Gene therapy (AAV vector) · Gene replacement · developed by UniQure Biopharma B.V.
rAAV2/5-hNAGLU is an AAV5-based gene therapy carrying the human NAGLU gene, delivered by one-time intraparenchymal injection into the brain. It is studied in Sanfilippo syndrome type B (mucopolysaccharidosis III), a lysosomal storage disease caused by NAGLU deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03300453 | Phase 1/2 | Sanfilippo Syndrome B | Completed | QURE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Sanfilippo Syndrome B
Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.
See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QURE catalysts and pipeline →